Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A

Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A

SSZSE:300534
8.91
CNY
-0.64
(-6.70%)
0.15EPS
155.29P/E
3.82BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.31
1.33
1.22
1.09
0.89
0.67
0.79
0.84
0.95
2.64
3.56
3.44
2.92
2.34
Basic EPS, GAAP
0.19
0.27
0.27
0.19
0.06
0.04
0.04
0.01
-0.03
0.13
0.2
0.08
0.14
0.08
Free Cash Flow per Basic Share
-0.12
-0.27
-0.59
-0.16
-0.19
0.02
- -
0.08
0.17
0.8
-0.1
0.45
-0.16
- -
Dividend per Share
0.06
0.09
0.11
0.03
0.03
0.01
0.01
0.02
- -
- -
0.01
0.05
0.05
0.03
Book Value per Share
1.4
1.6
1.78
2.32
2.35
2.38
2.41
2.4
2.37
2.73
2.09
2.21
2.34
2.33
Tangible Book Value per Share
1.39
1.59
1.78
2.15
2.19
2.2
2.18
2.17
2.16
2.48
1.84
1.96
2.05
2.04
Basic Weighted Avg Shares
210
228
227
246
303
303
304
305
304
303
303
303
303
303
Sales/Revenue/Turnover
275
302
277
270
270
203
239
255
288
800
1,080
1,043
887
710
Operating Margin (%)
15.56
21.83
26.25
18.51
6.92
7.35
9.75
1.91
-1.79
8.03
9.38
9.46
11.9
10.87
Depreciation Expense
3
3
3
6
16
18
20
20
23
27
30
38
44
- -
Net Income, GAAP
41
60
61
47
17
12
13
2
-9
39
62
24
44
25
Effective Tax Rate (%)
15.07
14.99
15.68
13.67
5.54
9.16
23.31
14.03
- -
26.44
13.57
50.78
19.45
32.54
Profit Margin (%)
14.88
20.04
21.88
17.52
6.35
6.04
5.35
0.72
-3.16
4.85
5.71
2.35
4.96
3.46
Working Capital
289
283
215
242
209
222
212
230
240
320
209
172
197
223
LT Debt
50
50
150
10
10
- -
- -
- -
- -
- -
113
98
106
106
Total Equity
319
363
406
704
712
721
739
739
733
883
712
740
781
791
Return on Invested Capital (%)
13.66
14.6
11.8
6.7
2.39
1.71
2.03
0.25
- -
5.6
9.2
5.81
8.83
5.46
Return on Capital (%)
14.83
15.46
12.44
7.42
2.43
1.74
1.44
0.27
- -
3.58
4.86
0.05
2.72
0.67
Return on Common Equity (%)
16.69
17.72
15.79
8.52
2.42
1.71
1.76
0.25
-1.26
5.01
8.43
3.75
6.37
3.53

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
50
18
34
LT Borrowings
103
103
103
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
303
303
303
Market Capitalization
2,830
2,148
3,816

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
685
589
592
Cash, Cash Equivalents & STI
235
169
211
Accounts Receivable, Net
288
242
214
Inventories
110
118
105
Total Current Liabilities
445
357
369
Payables & Accruals
- -
- -
- -
ST Debt
50
18
34
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.83%
1.96%
5.6%
Free Cash Flow
-859.51%
-65.64%
-136.36%
Net Income, GAAP
-124.08%
-209%
79.56%
Sales/Revenue/Turnover
20.43%
41.48%
-14.92%
Total Cash Common Dividend
79.42%
175.51%
-4.74%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
255
296
255
233
1,043
2025
275
207
151
255
887
2026
232
101
123
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
- -
0.01
- -
0.08
2025
0.06
0.01
- -
0.07
0.14
2026
0.08
-0.04
-0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
0.11
-0.09
0.05
2025
0.04
-0.01
- -
- -
0.05
2026
- -
0.02
- -
- -
- -

Company Description

CEO
Yue Hong Song
Full Time Employees
641
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 10 Guofang Road Lanzhou GA China 730102
IPO Date
Sep 13, 2016
Website
lsrfzy.com
Business
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD is a China-based pharmaceutical company primarily engaged in the research, development, production, and sales of Chinese patent medicines, health food products, and active pharmaceutical ingredients (APIs). The company offers a broad product portfolio including Chinese proprietary medicines such as Lung Relief Tonic, Yuanhu Pain Relief Drops, Jujube Kernel Oil Drops, Berberine Tannic Acid Membranes, Shichiwei Wenyang Capsules, Apricot Cough Relief Capsules, Compound Salvia Tablets, Sanqian Medicine Tablets, Anti-inflammatory Cholesterol Tablets, Astragalus Angelica Capsules, Conjugation Tablets, and various pediatric formulations such as Pediatric Lung Clearing Tablets and Pediatric Cough Cleanse Tablets. Additionally, it manufactures chemical pharmaceutical preparations and intermediates, and related health care products. The company operates mainly in China and holds multiple certifications and honors including provincial technology center status, famous brand recognition, and awards for innovation and quality. Founded in 2002 and headquartered in Gansu, China, it is listed on the Shenzhen Stock Exchange (Ticker: 300534.SZ) and controlled by Gansu Pharmaceutical Investment Group Co., Ltd. Recent major company developments include the strategic acquisitions of Gansu Puan Pharmaceutical Co., Ltd in 2023 and Gansu Pharmaceutical Group Science and Technology Innovation Research Institute Co., Ltd in 2025. These acquisitions have strengthened its capital base and enhanced its market competitiveness and profitability. Its holding subsidiary has also obtained a renewed drug manufacturing license, reflecting continuous regulatory compliance and operational capability. The company focuses on integrating capital and assets to drive growth while expanding its R&D capabilities and product offerings in the pharmaceutical and health food sectors.